Orphan drug treatment
Search documents
Theravance Biopharma, Inc. (TBPH) Discusses Ampreloxetine Phase 3 Program and Unmet Need in Neurogenic Orthostatic Hypotension with Multiple System Atrophy Transcript
Seeking Alpha· 2025-12-08 23:47
PresentationI'd now like to turn the call over to Rick Winningham, Chief Executive Officer at Theravance Biopharma. Please go ahead, Rick.Good morning and welcome to the Theravance Biopharma KOL event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Theravance website following the conclusion of the event.Rick WinninghamCEO & Director Good morning, and thank you for joining us. We're excited to host this KOL event focused on ampreloxetine, a med ...